Replidyne (Nasdaq:RDYN) unterbewertete Biotech Perle mit... - 500 Beiträge pro Seite

[stockinside]

Replidyne (Nasdaq:RDYN) unterbewertete Biotech Perle mit sehr guter Pipline, über 80$ Mio bar, bei einer Markt Cap. von nur 34 Mio$!!!

Allgemeine Informationen



Firma: Replidyne Inc.
Land: USA
Branche: Medizin
Heimatbörse: Nasdaq
Land: USA

Technische Informationen
Kürzel: RDYN
Kurs 1,38$

52wk Range: 1.26$ - 7.50$

Ich denke das Tief bei 1,26$ (1,3$) haben wir gesehen

Market Cap: 37.34M $

RYDN hat fast 80 Mio. $ million in cash
Info finden Sie hier: http://biz.yahoo.com/e/080509/rdyn10-q.html
Auf der Firmen Webseite steht noch 90 Mio$
http://www.replidyne.com/content/index.cfm?fuseaction=showCo…

Ich sehe ein 100% Chance ohne News, mutige steigen jetzt ein!

Auf jeden Fall ein gutes Invest bei der Pipeline, es wird spekuliert, das News anstehen könnten!

Schauen Sie sich die Pipeline an!!!


Great Progress in Replidyne’s Pipeline
http://seekingalpha.com/article/66685-great-progress-in-repl…


Replidyne, Inc. is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing anti-infective products. Its most advanced product candidate, faropenem medoxomil, is an oral, community antibiotic being developed for adult primary care and pediatric uses. Its second product candidate, REP3123, is a new, narrow spectrum antibacterial agent for the treatment of Clostridium difficile (C. difficile) bacteria and C. difficile-associated disease. REP3123 is being developed under its methionyl tRNA synthetase inhibitor program, which also included REP8839. REP8839 was being developed for treating skin and wound infections. The Company announced in December 2007, that it had suspended further development work on REP8839. The Company is also pursuing the development of other compounds that inhibit bacterial DNA replication.


1 Jahr


6 Monate

Profile
Strong Pipeline
# Faropenem medoxomil is an oral antibiotic in Phase III clinical trials for adult patients and in Phase II clinical trials for pediatric patients
# C. difficile is a preclinical program for intestinal tract diseases
# DNA replication is a discovery program to develop novel antimicrobial agents

Supported By Investment Community
Raised $62.5 million in private equity financing in fall 2005
Raised $44.5 million in IPO in July 2006

Active Business Development
# Acquired faropenem medoxomil from Asubio Pharma in 3/04
# Received $60 million in payments from Forest Laboratories in 2006
# Pursuing new opportunities in anti-infectives, pediatrics, and other

weitere Infos unter http://www.replidyne.com


Info vom 29.4.08

I remain incredibly optimistic about Replidyne’s (RDYN), a leader in next-generation anti-infective products, direction (note: this in no way should be interpreted as investment advice). After being dealt a bum deal by the FDA re: a change in protocol for antibiotic trials, management at Replidyne has retrenched.

With $90.3M in cash on the books as of 31 December 2007, and a quarterly burn of approximately $18M, it is full steam ahead with the Faropenem asset, as Phase III enrollment continues for treatment of acute exacerbation of chronic bronchitis. Preparation for three additional Phase III trials is likewise underway, one for treatment of acute bacterial sinusitis and two for treatment of community acquired pneumonia.

The search continues for a partner on the Faropenem asset, and when and if one is identified and announced, I would have to venture a guess that there will be a significant step up in value from today’s ~$53M market cap, which by the way indicates that the entity is trading below the sum of its parts.

Finally, great progress is being made in the pipeline with an expected IND filing this year for REP3123 in the Clostridium difficile program, and there is also an expectation for the identification of an IND candidate in the DNA replication inhibition program as an additional 2008 milestone.


Five Cheapest Stocks by Multiple Measures

Replidyne is a biotech company focused on anti-infective drugs. Its lead candidate is Orapem, a Phase III oral antibiotic, and it\'s also working on a Phase I topical antibiotic that will treat staph infections in hospitals. The good news is that growing bacterial resistance has created a demand for stronger anti-infective drugs, and that if Orapem is approved it will be the first U.S. beta-lactam stronger than penicillin, and that beta-lactams comprise 70% of the pediatric antibiotic market. The bad news is that Orapem hasn\'t been approved and that\'s cost Replidyne its partner, Forest Labs (FRX), which was planning to provide both development and marketing for the drug. As with so many biotechs, this one looks like a crapshoot on FDA approval.

http://seekingalpha.com/article/74608-five-cheapest-stocks-b…

Ich denke das Tief bei 1,26$ (1,3$) haben wir gesehen

[BrauchGeld]

@ Stockinside

Wenn du schon was empfiehlst dann solltest du auch die negativen Punkte erwähnen

- Partner Forest Lab ist abgesprungen
- Phase III (Bronchitis) abgebrochen
- 2006 gabs ein non-approval für Faropenem von der FDA
- Cash ist gut aber ohne Produkte auch nicht viel wert

Fazit : Die Aktie ist zurecht verprügelt worden und ich sehe keinen Grund warum die Aktie steigen sollte .

http://biz.yahoo.com/prnews/080507/law029.html?.v=101

Replidyne reported a net loss of $9.0 million for the first quarter ended March 31, 2008, or a net loss per basic and diluted common share of $0.33 per share, compared to a net loss of $8.6 million, or $0.32 per basic and diluted common share, for the first quarter ended March 31, 2007. Cash, cash equivalents and short-term investments at March 31, 2008 totaled $78.1 million.

On April 23, 2008, subsequent to the conclusion of the first quarter, Replidyne announced it had discontinued enrollment in a placebo-controlled Phase III clinical trial testing faropenem medoxomil (faropenem) in patients with acute exacerbation of chronic bronchitis (AECB) and restructured its operations. As a result, the Company will incur approximately $1.8 million of expense, including $1.4 million of future employee severance related expense. Replidyne took these actions to conserve cash assets and support ongoing strategic initiatives.

"We have made difficult decisions and taken significant action this year," said Kenneth J. Collins, Replidyne's President and CEO. "By discontinuing enrollment in the AECB study and restructuring our workforce, we are limiting spending to conserve our strong financial base. We believe these actions will enable us to act opportunistically in pursuing a strategic transaction."


http://www.bizjournals.com/denver/stories/2008/03/31/daily24…
Tuesday, April 1, 2008
Replidyne dangles bonuses in front of two execs

Biotechnology company Replidyne Inc. will pay its CFO and corporate development officer bonuses of up to $250,000 if they remain with the company through a looming strategic transaction with another company.

The company said in a Securities and Exchange Commission filing Tuesday that it would pay Donald Morrissey, senior vice president of corporate development, and CFO Mark Smith bonuses of $100,000 to keep working for Replidyne (NASDAQ: RDYN) through Sept. 30, and another $150,000 if they stay on through the completion of the unspecified deal with another company.

The Louisville company has indicated in the past that it needed a partner to finance development of its antibiotic drug faropenem medoxomil.

The federal Food and Drug Administration rejected faropenem medoxomil for sale in the United States in late 2006 without further clinical trials. An easier path to approval had been expected, but regulators began raising standards for the approval of new antibiotics in midst of Replidyne's effort to get its drug approved.

That rejection caused Forest Laboratories Inc., a New York-based pharmaceutical giant, to end a partnership with Replidyne in early 2007, which cost the company up to $190 million in research help from Forest.

In December, Replidyne cut its staff by 35 percent, to 54 workers, and said it would halt research beyond the ongoing clinical trial of faropenem medoxomil for use as treatment for acute exacerbation of chronic bronchitis until a partner could be found to help pay for testing the drug for other uses.

[stockinside]

@BrauchGeld

Möchte auf Deine Punkte kurz eingehen!


- Phase III (Bronchitis) abgebrochen
=> Abgebrochen ist Sie nicht, ausgesetzt! Sie suchen einen Partner!
- 2006 gabs ein non-approval für Faropenem von der FDA
=> ist 2006 vom Markt bestraft worden, wir haben 2008!
- Cash ist gut aber ohne Produkte auch nicht viel wert
=> Produkte und eine sehr gute Pipeline vorhanden!

Bitte lass uns in 3 Wochen einmal über Replidyne reden

Ich denke schon nächste Woche geht´s weiter nach oben!